Acute toxicity after CyberKnife-delivered hypofractionated radiotherapy for treatment of prostate cancer

CyberKnife-delivered hypofractionated radiotherapy for the treatment of prostate cancer has an acceptable acute toxicity profile.

CyberKnife hypofractionated stereotactic radiotherapy as salvage for progressive malignant brain tumors

Thirteen of the 18 tumors (72%) showed a volume decrease. The average volume change was a decrease of 16 +/- 58% (median: 20%) with a follow-up of 180 +/- 121 days (median: 172 days). Toxicity occurred in only one patient, with symptoms improving on steroids.

Optic Apparatus Meningioma

Treatment with CyberKnife radiosurgery utilizing a hypofractionated treatment regimen was indicated for maximum local control and to minimize injury to the optic apparatus.